.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BC04_Flecainide.Flecainide

Information

Flecainide is a class Ic antiarrhythmic agent used to prevent and treat several types of serious cardiac arrhythmias, including paroxysmal supraventricular tachycardia and atrial fibrillation. It acts as a sodium channel blocker to stabilize cardiac electrical activity. Flecainide is approved and in clinical use in various countries.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.

References

1. Doki, K, et al., & Kohda, Y (2007). Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. European journal of clinical pharmacology 63(10) 951–957. DOI:10.1007/s00228-007-0348-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17665182

2. Doki, K, et al., & Kohda, Y (2006). Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. European journal of clinical pharmacology 62(11) 919–926. DOI:10.1007/s00228-006-0188-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16944116

3. Doki, K, et al., & Kohda, Y (2012). CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis. Pharmacogenetics and genomics 22(11) 777–783. DOI:10.1097/FPC.0b013e3283588fe5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22941032

Revisions

• 06/2025 initial generated model